4.3 Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs Suspensions
Key Takeaways
- Metered-Dose Inhalers (MDIs) utilize hydrofluoroalkane (HFA) propellants requiring a slow, deep inhalation over 3–5 seconds, a 10-second breath-hold, routine shaking before actuation (except solution MDIs), regular device priming, and spacer compatibility.
- Dry-Powder Inhalers (DPIs) are breath-actuated devices requiring a quick, forceful, deep inhalation without propellants; they must NEVER be shaken, must NEVER be used with a spacer, and inhalation capsules (Spiriva HandiHaler) must NEVER be swallowed orally.
- Soft Mist Inhalers (Respimat) deliver a slow-moving, long-lasting aerosol mist generated by mechanical spring tension rather than propellants, requiring a structured 'TOP' preparation sequence (Turn base, Open cap, Press button).
- Orally Disintegrating Tablets (ODTs) dissolve rapidly on the tongue via saliva without water and require peel-back blister foil handling to prevent crushing from moisture or pressure; Sublingual Nitroglycerin (Nitrostat) dissolves under the tongue to bypass first-pass metabolism and must remain in its original amber glass container with a tight metal cap.
- Oral liquid dosage forms require strict vehicle verification: Solutions are homogeneous active ingredients completely dissolved in vehicle (no shaking needed); Suspensions contain insoluble dispersed drug particles mandating 'Shake Well' auxiliary labeling and precise reconstitution measurement; Elixirs contain hydroalcoholic vehicles (contraindicated in children/disulfiram patients).
Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs. Suspensions
Core Verification Rule: Specialized drug delivery platforms—including pulmonary aerosol inhalers, transmucosal fast-dissolving tablets, and dispersed liquid systems—rely on specific physical principles to ensure clinical efficacy. Verifying technicians must verify not only the chemical entity and strength, but also device integrity, actuation counters, protective packaging, reconstitution diluent volumes, and route-specific auxiliary warning labels.
Technicians performing final verification encounter a wide array of specialized drug delivery systems designed to bypass hepatic metabolism, optimize pulmonary deposition, or overcome patient-specific administration barriers. Masterful technical verification requires a granular understanding of each delivery platform.
1. Pulmonary Inhalation Devices: MDI vs. DPI vs. SMI (Respimat)
Inhalation devices deliver active drugs directly into the bronchial airways to treat asthma and chronic obstructive pulmonary disease (COPD). The three primary device classes differ fundamentally in their propellant mechanics, inspiratory flow requirements, and handling protocols.
┌──────────────────────────────────────────────────────────────────────────────────┐
│ PULMONARY INHALATION PLATFORM COMPARISON │
├──────────────────────────┬───────────────────────────┬───────────────────────────┤
│ Feature / Parameter │ Metered-Dose Inhaler (MDI)│ Dry-Powder Inhaler (DPI) │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Propellant System** │ **Hydrofluoroalkane (HFA)**│ **None (Breath-Actuated)**│
│ │ Chemical propellant pushes│ Patient's inspiratory flow│
│ │ aerosol out of canister │ aerosolizes dry powder │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Inhalation Technique** │ **Slow and Deep** │ **Quick and Forceful** │
│ │ Inhale over 3 to 5 seconds│ Inhale rapidly & deeply │
│ │ simultaneously with press │ to de-aggregate powder │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Shake Before Use?** │ **YES** (Shake 5 seconds; │ **NO! NEVER SHAKE!** │
│ │ except QVAR/Alvesco) │ Shaking spills powder │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Spacer Compatibility** │ **YES** (Highly recommended│ **NO! NEVER USE SPACER!** │
│ │ with valved holding chamb)│ Obstructs powder flow │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Priming Required?** │ **YES** (Before first use │ **NO** (Load blister or │
│ │ or if unused for days) │ puncture capsule only) │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Breath-Hold Time** │ **10 Seconds** (or as │ **10 Seconds** (or as │
│ │ long as comfortable) │ long as comfortable) │
├──────────────────────────┼───────────────────────────┼───────────────────────────┤
│ **Representative Brands**│ ProAir HFA, Ventolin HFA, │ Advair Diskus, Spiriva │
│ │ Flovent HFA, Symbicort │ HandiHaler, Pulmicort │
│ │ HFA, Dulera HFA │ Flexhaler, Breo Ellipta │
└──────────────────────────┴───────────────────────────┴───────────────────────────┘
A. Metered-Dose Inhalers (MDIs) and Spacer Mechanics
- Mechanism: Drug is dissolved or suspended in a liquefied HFA propellant under pressure. Pressing the canister releases a single measured micro-spray.
- Priming Protocols: When an MDI is brand new or has sat unused for a specified period (e.g., Ventolin HFA: 4 test sprays if unused >14 days; ProAir HFA: 3 test sprays if unused >14 days; Symbicort: 2 test sprays if unused >7 days), propellant and drug separate in the valve chamber. Priming test sprays into the air away from the face re-establishes uniform drug concentration.
- Spacer / Valved Holding Chamber (VHC): Spacers attach to the MDI mouthpiece. Actuating the MDI into the chamber suspends the aerosol plume for several seconds, allowing the patient to inhale the medication smoothly without requiring precise hand-breath coordination. Spacers also reduce large particle deposition in the oropharynx, decreasing local side effects.
B. Dry-Powder Inhalers (DPIs) and Inhalation Capsules
- Mechanism: Micronized active drug is blended with larger lactose carrier particles. The patient's rapid, forceful inhalation creates turbulent airflow within the device, separating the microscopic drug particles from the lactose and carrying them deep into the terminal bronchioles.
[!CAUTION] Critical Inhalation Capsule Verification Hazard (Spiriva HandiHaler / Arcapta Neohaler): Single-dose DPIs utilize an aluminum blister package containing hard gelatin capsules (e.g., tiotropium in Spiriva HandiHaler). The capsule is placed inside the chamber of the HandiHaler device and pierced by pressing a piercing button; the patient then inhales the dry powder through the mouthpiece.
Catastrophic Verification / Administration Error: Patients frequently mistakenly swallow these capsules orally with water instead of inhaling them through the HandiHaler device. Swallowed tiotropium has <2% oral bioavailability and provides zero pulmonary bronchodilation. Verifying technicians must confirm that the prescription container carries the bold auxiliary warning: "FOR INHALATION ONLY — DO NOT SWALLOW CAPSULES."
C. Soft Mist Inhalers (SMIs - Respimat)
- Mechanism: Respimat devices deliver a slow-moving, long-lasting aerosol mist generated by mechanical spring compression rather than chemical propellants.
- The 'TOP' Preparation Sequence:
- Turn (T): Rotate the clear base half a turn in the direction of the arrows until it clicks.
- Open (O): Flip the protective cap fully open.
- Press (P): Point toward the ground and press the dose-release button.
D. Inhaled Corticosteroid (ICS) Mouth Rinsing Mandate
When verifying any inhaler containing an Inhaled Corticosteroid (e.g., Flovent HFA [fluticasone], Pulmicort [budesonide], QVAR [beclomethasone], Advair [fluticasone/salmeterol], Symbicort [budesonide/formoterol], Breo Ellipta [fluticasone/vilanterol]), the technician must ensure the following auxiliary label is affixed:
┌────────────────────────────────────────────────────────────────────────┐
│ [ AUXILIARY LABEL: RINSE MOUTH AND SPIT OUT AFTER EACH USE ] │
│ Prevents fungal ORAL CANDIDIASIS (thrush) and DYSPHONIA (hoarseness) │
│ caused by local corticosteroid immunosuppression in the oropharynx. │
└────────────────────────────────────────────────────────────────────────┘
2. Transmucosal and Fast-Dissolving Oral Solids: ODTs, Sublingual, and Buccal
Oral solid dosage forms that dissolve in the oral cavity provide rapid therapeutic onset, eliminate the need for swallowing water, or protect active drugs from first-pass hepatic clearance.
┌────────────────────────────────────────────────────────────────────────┐
│ ORAL CAVITY TRANSMUCOSAL DELIVERY PLATFORMS │
├───────────────────┬────────────────────────────────────────────────────┤
│ Formulation Class │ Anatomical Site & Pharmacokinetic Action │
├───────────────────┼────────────────────────────────────────────────────┤
│ **ODT** │ Placed on the tongue; disintegrates in saliva in │
│ (Orally │ seconds. Swallowed with saliva; absorbed through │
│ Disintegrating) │ gastrointestinal tract. (Ondansetron ODT, Mirtaz.) │
├───────────────────┼────────────────────────────────────────────────────┤
│ **Sublingual** │ Placed directly UNDER the tongue. Dissolves in │
│ (SL) │ sublingual mucosa; absorbed directly into venous │
│ │ circulation, BYPASSING FIRST-PASS LIVER METABOLISM.│
│ │ (Nitrostat nitroglycerin, Suboxone SL film) │
├───────────────────┼────────────────────────────────────────────────────┤
│ **Buccal** │ Placed in the BUCCAL POUCH (between cheek and upper│
│ │ gum). Dissolves slowly for transmucosal systemic │
│ │ absorption. (Fentora buccal fentanyl, Belbuca) │
└───────────────────┴────────────────────────────────────────────────────┘
A. Orally Disintegrating Tablets (ODTs): Packaging and Moisture Fragility
- Mechanism: Formulated via lyophilization (freeze-drying) or fast-dissolving superdisintegrants (crospovidone). Disintegrates on the tongue within 5 to 15 seconds without water.
- High-Yield Verification Checkpoint: ODTs (e.g., Zofran ODT [ondansetron], Remeron SolTab [mirtazapine], Fazaclo [clozapine]) are highly friable (easily crumbled) and extremely hygroscopic (absorb moisture from air).
- Packaging Rule: ODTs must remain sealed in their unit-dose blister packaging until immediately before use. Patients must peel back the foil blister with dry hands rather than pushing the tablet through the foil (which crushes the fragile wafer).
B. Sublingual Nitroglycerin (Nitrostat) Verification and Storage Rules
Sublingual nitroglycerin tablets (Nitrostat 0.3 mg, 0.4 mg, 0.6 mg) are among the most chemically volatile medications in pharmacy inventory. Because nitroglycerin is a volatile organic nitrate with a high vapor pressure, strict packaging and storage rules apply:
┌────────────────────────────────────────────────────────────────────────┐
│ NITROSTAT (SUBLINGUAL NTG) VERIFICATION RULES │
├────────────────────────────────────────────────────────────────────────┤
│ 1. ORIGINAL AMBER GLASS CONTAINER MANDATE: Must ALWAYS be dispensed │
│ in the manufacturer's original amber glass bottle with a tight │
│ metal screw-cap. NEVER repackage into standard amber plastic vials │
│ (nitroglycerin binds to and adsorbs onto plastic polymers). │
│ │
│ 2. NO DESICCANT REMOVAL: Do not remove the internal desiccant pack or │
│ cotton plug unnecessarily; keep tightly capped immediately after use│
│ to prevent evaporation and moisture-induced hydrolysis. │
│ │
│ 3. EXPIRATION DATING: Standard practice dictates discarding opened │
│ bottles 6 months after opening (or per manufacturer expiration). │
│ │
│ 4. ADMINISTRATION DIRECTIVE: Dissolve under the tongue at the first │
│ sign of acute angina. Do not chew, crush, or swallow whole. │
└────────────────────────────────────────────────────────────────────────┘
3. Liquid Oral Dosage Forms: Solutions, Suspensions, Syrups, and Elixirs
Oral liquids are essential for pediatric patients, geriatric patients with dysphagia, and patients requiring enteral tube feeding. The verifying technician must distinguish between homogeneous and heterogeneous liquid delivery systems.
ORAL LIQUID VEHICLE HIERARCHY
┌────────────────────────────────────────────────────────────────────────┐
│ HOMOGENEOUS (Completely Dissolved) │ HETEROGENEOUS (Two-Phase Disperse│
├──────────────────────────────────────┼─────────────────────────────────┤
│ • SOLUTIONS: Clear aqueous mixtures │ • SUSPENSIONS: Solid insoluble │
│ • SYRUPS: High-sucrose viscous │ particles dispersed in vehicle│
│ • ELIXIRS: Hydroalcoholic solutions │ (MANDATORY SHAKE WELL!) │
│ (No particulate settling occurs) │ • EMULSIONS: Immiscible liquids │
└──────────────────────────────────────┴─────────────────────────────────┘
Comprehensive Liquid Dosage Form Matrix:
| Liquid Formulation Type | Physical Structure & Ingredients | High-Yield TPV Verification Requirements & Safety Alerts |
|---|---|---|
| Oral Solution | Homogeneous mixture where active solute is completely dissolved in a liquid solvent (water). Optically clear, uniform dosing throughout. | Does not settle upon standing; does not require vigorous shaking (though gentle inversion is acceptable). Check clarity; verify absence of precipitation or cloudiness. |
| Oral Suspension | Heterogeneous two-phase system consisting of finely divided, insoluble solid drug particles suspended in a liquid vehicle. Particles settle over time per Stokes' Law. | MANDATORY 'SHAKE WELL BEFORE USING' AUXILIARY LABEL. Failure to shake causes severe underdosing initially, followed by lethal toxic overdosing when reaching the concentrated sediment at the bottom. |
| Oral Syrup | Concentrated aqueous solution of sugar (e.g., 60% to 85% sucrose w/v or sorbitol) containing flavoring and active drug. Viscous, sweet. | Sugar concentration creates low water activity ($a_w$), inhibiting bacterial growth without added preservatives. Caution in diabetic patients (screen for sugar-free alternatives). Provides soothing demulcent effect for cough. |
| Oral Elixir | Clear, sweetened hydroalcoholic solution (water + ethanol, typically 5% to 40% alcohol) designed to solubilize poorly water-soluble APIs. | CONTRAINDICATED IN PEDIATRIC PATIENTS and patients taking medications that cause disulfiram-like reactions (e.g., metronidazole, tinidazole). Verify ethanol content against patient age. |
| Oral Emulsion | Two-phase system of two immiscible liquids (oil-in-water or water-in-oil) stabilized by an emulsifying agent (e.g., acacia, polysorbate). | Requires 'Shake Well' label. Inspect for irreversible 'cracking' or phase separation where oil and water layers permanently separate. |
Oral Antibiotic Suspension Reconstitution Protocols
Reconstituting dry antibiotic powders (e.g., amoxicillin, cephalexin, Augmentin, cefdinir, azithromycin) requires rigorous technical precision:
┌────────────────────────────────────────────────────────────────────────┐
│ ANTIBIOTIC RECONSTITUTION VERIFICATION PROTOCOL │
├────────────────────────────────────────────────────────────────────────┤
│ 1. Tap the dry powder bottle firmly against a counter to loosen │
│ compacted powder from the base. │
│ 2. Measure the exact volume of PURIFIED WATER USP (or distilled water) │
│ specified on the manufacturer stock label using a calibrated syringe│
│ or graduated cylinder. NEVER use tap water. │
│ 3. Add APPROXIMATELY HALF (50%) of the measured water to the bottle. │
│ 4. Cap tightly and shake vigorously to wet and suspend the powder. │
│ 5. Add the REMAINING WATER up to the exact total volume. │
│ 6. Shake vigorously again until all powder is completely suspended. │
│ 7. Affix auxiliary labels: │
│ • [ SHAKE WELL BEFORE USING ] │
│ • [ REFRIGERATE - DO NOT FREEZE ] (if required, e.g., Augmentin) │
│ • [ FINISH ALL MEDICATION ] │
│ • [ DISCARD AFTER X DAYS ] (e.g., 10 days or 14 days beyond-use) │
└────────────────────────────────────────────────────────────────────────┘
A patient diagnosed with moderate persistent asthma receives a new prescription for Advair Diskus (fluticasone/salmeterol) dry-powder inhaler (DPI). Which instruction correctly reflects the mechanical operation and administration technique for this device?
During product verification of a new prescription for Spiriva HandiHaler (tiotropium bromide inhalation powder capsules), what critical route-specific auxiliary warning label must the technician ensure is affixed to the dispensing container?
A technician is verifying a prescription for Nitrostat 0.4 mg sublingual nitroglycerin tablets. Which packaging and storage requirement is mandatory prior to releasing this product to the patient?
A pharmacy technician is verifying a reconstituted oral suspension of cefdinir 250 mg/5 mL. What fundamental physical difference distinguishes a pharmaceutical suspension from an oral solution, and what auxiliary labeling is mandatory?